Epigenetic Aging Clocks Predict Alzheimer's Biomarkers in Hispanic Adults

This groundbreaking study examined whether epigenetic aging clocks can predict blood-based biomarkers of Alzheimer's disease in a large, diverse population. Researchers analyzed data from 2,656 Hispanic/Latino adults (average age 62.5 years, 65% female) participating in the Study of Latinos-Investigation of Neurocognitive Aging.

The team measured five different epigenetic clocks - mathematical models based on DNA methylation patterns that estimate biological aging - and compared them to plasma levels of key Alzheimer's biomarkers. These included amyloid beta proteins (Aβ40, Aβ42), phosphorylated tau (p-Tau181), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP).

All five epigenetic clocks showed significant associations with higher NfL levels, a marker of neuronal damage and neurodegeneration. Four of the five clocks also correlated with elevated Aβ40 levels. Most notably, the second-generation PC-PhenoAge clock demonstrated consistent associations across all biomarkers, suggesting it may best capture the biological processes underlying age-related brain changes.

Important sex differences emerged in the analysis. PC-PhenoAge acceleration was associated with higher Aβ42 and p-Tau181 levels in males but not females, while it correlated with lower Aβ42/40 ratios in females but not males. These findings highlight the importance of considering biological sex when interpreting aging biomarkers.

The results suggest that epigenetic aging acceleration may serve as an early indicator of Alzheimer's-related brain changes, potentially years before clinical symptoms appear. This could revolutionize early detection strategies, particularly in underrepresented populations like Hispanic/Latino communities who face disproportionate dementia risks but are often excluded from research studies.